SEC Form 4 · accession 0001123292-17-000941
Recro Pharma, Inc. · REPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Karen Flynn
Director
Period of report
May 12, 2017
Accepted (ET)
May 16, 2017 · 4:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001588972
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | May 12, 2017 | A | 13,274 | A | — | — | Common Stock | 13,274 | 13,274 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.
- F2The restricted stock units vest on May 12, 2018. Vested shares will be delivered to the reporting person within 30 days following the vesting date.